HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (āFibroBiologicsā), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete OāHeeron, will present at the H.C. Wainwright 27thĀ Annual Global Investment Conference taking place September 8-10 at the Lotte New York Palace Hotel in New York City.